Tagrisso plus chemotherapy improves survival in EGFR-mutated advanced lung cancer
TL;DR
AstraZeneca's FLAURA2 Phase III trial shows that combining Tagrisso with chemotherapy significantly improves overall survival in patients with EGFR-mutated advanced non-small cell lung cancer, reinforcing Tagrisso as a key treatment option across stages.
- Tagrisso plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer AstraZeneca
- AstraZeneca's Tagrisso, chemo regimen hits survival goal in lung cancer trial FirstWord Pharma
- Survival data back Tagrisso's role in first-line lung cancer pharmaphorum
- TAGRISSO® (osimertinib) plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer Business Wire
- AstraZeneca shares late-stage results for Tagrisso combination in lung cancer PMLiVE
Want the full story? Read the original reporting
Read on AstraZeneca